ERASCA INC (ERAS)
Sector: Health Care
2026 Annual Meeting Analysis
ERASCA INC · Meeting: June 26, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors for a Three-Year Term Expiring at the 2029 Annual Meeting
Casdin has served since July 2018 and brings deep biopharma financial expertise; ERAS's 3-year price return of +267% outpaces the XBI — SPDR S&P Biotech ETF by +206 percentage points, far exceeding the 65-point threshold required to trigger a performance-based concern, so no TSR flag applies, all meetings were attended, no overboarding issues were identified, and he is properly classified as independent despite serving as Audit Committee Chair with confirmed financial expert designation.
Hambleton has served since March 2021 and contributes extensive oncology and biopharma clinical development experience; the same strong ERAS 3-year TSR of +267% versus the XBI — SPDR S&P Biotech ETF (+61%) produces a gap of +206 percentage points, well above the 65-point trigger threshold meaning no underperformance concern exists, attendance was satisfactory, and she serves appropriately as an independent director on the Audit and Compensation committees.
Varney has served since December 2020 and brings decades of drug discovery and development leadership from Genentech and Agouron; while he is classified as non-independent due to his paid employee role as Chair of R&D, he does not sit on the Audit or Compensation committees, so no independence-on-committee flag is triggered, and the company's +267% 3-year return versus the XBI — SPDR S&P Biotech ETF produces a +206 percentage point outperformance gap that comfortably clears the 65-point threshold, leaving no TSR concern.
All three Class II nominees are supported. Erasca's stock has delivered extraordinary returns over the past three years — up about 267%, compared to roughly 61% for the XBI — SPDR S&P Biotech ETF — producing a +206 percentage point outperformance gap that is well above the 65-point threshold required to raise any performance-based board concern. Each nominee has relevant biopharma qualifications, adequate meeting attendance, and no overboarding issues. Varney's non-independent classification is noted but is not disqualifying because he sits on neither the Audit nor Compensation committees.
Say on Pay
✓ FORCEO
Jonathan E. Lim, M.D.
Total Comp
$4,298,838
Prior Support
N/A
The CEO's total compensation of approximately $4.3 million is composed primarily of variable pay — roughly $3.1 million in stock option awards and $483,000 in a performance-based annual bonus — meaning fixed base salary of $670,400 represents only about 16% of total pay, well within the 40% fixed-pay ceiling the policy requires. The annual bonus was paid at 120% of target based on achievement of disclosed clinical, regulatory, and financial milestones, which is a measurable performance link, and aligns with the company's exceptional stock performance over both the past year (+607%) and the past three years (+267% versus the XBI — SPDR S&P Biotech ETF's +61%). The company has adopted a Dodd-Frank compliant clawback policy covering Section 16 officers, and no prior Say on Pay vote result is disclosed in the filing, so no prior-year non-response flag is triggered.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$609,765
Non-Audit Fees
$1,780
Non-audit fees of $1,780 represent less than 1% of audit fees of $609,765, far below the 50% threshold that would raise independence concerns; KPMG is a Big 4 firm appropriate for Erasca's $3.1 billion market cap; auditor tenure is not explicitly disclosed in the proxy so the tenure trigger cannot fire under policy; and no material financial restatements were identified.
Overall Assessment
Erasca's 2026 annual meeting ballot contains two formal proposals — director elections and auditor ratification — with no Say on Pay vote formally on the ballot this year and no stockholder proposals submitted. All votes are FOR: the three Class II director nominees bring strong relevant credentials to a board overseeing a company whose stock has dramatically outperformed the XBI — SPDR S&P Biotech ETF over three years, and KPMG's fee structure is clean with non-audit fees representing less than 1% of audit fees.